Dr. Plimack details RETAIN, from early findings with neoadjuvant ddMVAC to the evolution of RETAIN-1 and RETAIN-2.
Muscle Invasive Urothelial Carcinoma
Latest News
Preliminary results of the study showed promising efficacy and safety with neoadjuvant treatment with DV plus toripalimab.
Drs. Ghatalia and Nizam break down in detail the RETAIN-2 study, a phase 2 trial of risk enabled therapy for MIBC.
Dr. Galsky highlights the latest findings on the impact of pCR on long-term outcomes in the NIAGARA trial.
Dr. Galsky provides comment on the additional efficacy outcomes in patients with MIBC from the CheckMate 274 study.
The interim analysis of the RETAIN-2 trial demonstrated a 46% pT0 rate among those undergoing cystectomy.
Nivolumab demonstrated sustained DFS benefits across all patients with MIBC and in prior NAC subgroups.
Urothelial Carcinoma Knowledge Hubs
Curated clinical content based on urothelial cancer types, therapies, and technologies
Conference Coverage
Noah Hahn, MD, gives an overview of durvalumab with intravesical gemcitabine and docetaxel for BCG-unresponsive NMIBC.
Dr. Daniel Joyce gives an overview of his study that examined the use of necrosis as a prognostic indicator for mRCC.
Drs. Karine Tawagi and Samantha Armstrong expand on the prostate cancer discussions of note, including TALAPRO-2.
Drs. Tawagi and Armstrong provide detail and discussion on the bladder cancer research from the 2025 ASCO GU meeting.
Drs. Tawagi and Armstrong recap the hottest topics in kidney cancer research from the 2025 ASCO GU Cancers Symposium.
Dr. Sonpavde provides an update on the latest analysis from the phase 3 global study of EV in combination with pembro.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.